share_log
Moomoo 24/7 ·  04/18 11:31

Ocular Therapeutix Shares Are Trading Lower. The Company Announced Topline Results From the Phase 1 HELIOS Study Evaluating AXPAXLI in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Ocular Therapeutix的股价正在走低。该公司公布了评估中重度至重度非增殖性糖尿病视网膜病变患者AXPAXLI的1期HELIOS研究的主要结果

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发